AbCellera Biologics Inc. (ABCL)
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
AbCellera Biologics Inc.
Trials need funding. See this company's dilution risk and cash position.
- Phase 1/2Active, not recruiting
Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause
ABCL635, Placebo
Vasomotor Symptoms Associated With Menopause, Healthy Volunteers
NCT07118891Enrollment136StartJun 2025Primary CompletionFeb 2027est.CompletionFeb 2027est. - Phase 1Active, not recruiting
A First-in-Human Phase 1 Single-Ascending Dose Study of ABCL575 in Healthy Participants
ABCL575, Placebo (Normal Saline 0.9%)
Healthy Volunteers
NCT07108894Enrollment40StartJul 2025Primary CompletionApr 2027est.CompletionApr 2027est.
| Drug / Therapy | Link | ||
|---|---|---|---|
| Phase 1/2 | Active, not recruiting | ABCL635, Placebo | NCT07118891 |
| Phase 1 | Active, not recruiting | ABCL575, Placebo (Normal Saline 0.9%) | NCT07108894 |